FDA: Ingredient Safety Decisions Under PCPSA Could Differ From CIR
This article was originally published in The Rose Sheet
Compared with the Cosmetic Ingredient Review, FDA could consider a wider selection of data in its ingredient safety evaluations under the Personal Care Products Safety Act, an FDA official says. Further, industry would have the burden of demonstrating reasonable certainty of no harm, a high bar to clear.
You may also be interested in...
FDA’s final rule is specific to lead acetate’s use in hair-coloring products, but the agency’s recognition of current consensus – “that there is no safe exposure level for lead” – could spook the wider cosmetics industry, particularly given that some of the same NGO petitioners that drove the rulemaking are clamoring for an all-out ban on trace lead in lipsticks and externally applied cosmetics.
Proposed regulatory reform legislation in the Senate would require FDA to review the safety of cosmetics ingredients, taking into account evaluations conducted by accredited third parties. In August, FDA requested quotes from the contractor community for developing a cosmetic hazard and risk assessment protocol and optional certification program “to show compliance with the protocol.”
ICMAD leadership agrees with Bailey that, now more than ever before, the pieces are in place for cosmetics reform legislation to reach the finish line. At the same time, the small-business advocate remains opposed to leading proposals, signaling the significant distance that negotiations may still have to go.